ArticleObesity (Silver Spring, Md.)2022
Use of prescription medications associated with weight gain among US adults, 1999-2018: A nationally representative survey.
Article in Obesity (Silver Spring, Md.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.JAMA network open · 2026Pooled it
- Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity.BMJ open diabetes research & care · 2026Review
- 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes-2026.Diabetes care · 2026Review
- A geriatrician's approach to managing the complex older adult with obesity.Obesity (Silver Spring, Md.) · 2025Review
- Plasma N-Glycoproteomics in monozygotic twin pairs discordant for body mass index reveals an obesity signature related to inflammation and iron metabolism.Biology direct · 2025Article
- Depression and Diet Quality, US Adolescents and Young Adults: National Health and Nutrition Examination Survey, 2015-March 2020.Journal of the Academy of Nutrition and Dietetics · 2025Article
- Obesogenic Medication Use in End-Stage Kidney Disease and Association With Transplant Listing.Clinical transplantation · 2024Article
- The healthcare costs of increased body mass index-evidence from The Trøndelag Health Study.Health economics review · 2024Article
- Weight Management Interventions Provided by a Dietitian for Adults with Overweight or Obesity: An Evidence Analysis Center Systematic Review and Meta-Analysis.Journal of the Academy of Nutrition and Dietetics · 2023Article
- Use of medications associated with weight change among participants in the All of Us research programme.Clinical obesity · 2023Article
- Burden of high-risk phenotype of heavy alcohol consumption among obese U.S. population: results from National Health and Nutrition Examination Survey, 1999-2020.Lancet regional health. Americas · 2023Article
- Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.EClinicalMedicine · 2023Review
- Validating cuffless continuous blood pressure monitoring devices.Cardiovascular digital health journal · 2023Review
- Obesogenic and leptogenic medication utilization in people with obesity: Is there a prescription for improvement?Lancet regional health. Americas · 2022Article
- Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study.Lancet regional health. Americas · 2022Article
- Weight gain after in vitro fertilization: a potential consequence of controlled ovarian stimulation.Journal of assisted reproduction and genetics · 2022Article
- Association Between Weight Promoting Medication Use and Weight Status Among Children and Adolescents in the United States.Academic pediatricsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveThis study aimed to evaluate trends in the use of obesogenic medications among adults.
methodsCross-sectional data on adults aged ≥20 years are from the 1999 to 2018 National Health and Nutrition Examination Survey (n = 52,340). Obesogenic medications were defined according to the 2015 Endocrine Society guidelines on the pharmacological management of obesity. Weight status was categorized according to BMI. Trends in prior 30-day use were evaluated.
resultsIn NHANES 2017-2018, 20.3% of US adults used an obesogenic medication. Beta-blockers (9.8%) and antidiabetics (5.7%) were the most common; antipsychotics (1.0%) were the least common. Most common indications were disorders of glucose metabolism, hypertension, neuralgia or neuritis, heart disease, and musculoskeletal pain and/or inflammation. From 1999 to 2018, the proportional use of obesogenic medications increased for anticonvulsants (34.4% to 55.0%) but decreased for antidepressants (32.1% to 18.8%), antidiabetics (82.9% to 52.5%), and beta-blockers (83.9% to 80.7%). The proportional use of obesogenic medications was not associated with weight status, except for antipsychotics.
conclusionsUse of obesogenic medications was common. Differences in the proportional use of obesogenic medication may reflect changing availability of obesogenic versus nonobesogenic medications over time. The decision to prescribe a nonobesogenic alternative, if one exists, is guided by weighing the risks and benefits of available treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.